Document -
Isofol Appoints the Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemotherapy Asset
Gothenburg, Sweden, Cambridge UK, and Clinton NJ – February 2015 – Isofol Medical announces that after a global program to identify one or more strategic partners for commercialization of its Modufolin® chemotherapy asset The Sage Group (based in Europe, USA and Asia) has been appointed to assist the company in this endeavor.
-
License:
© All rights reserved
The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
- File format: .pdf
